Precision BioSciences Inc. reported total revenues of less than $0.1 million for the third quarter ended September 30, 2025, compared to $0.6 million in the same period in 2024, primarily due to reduced billable effort under the Novartis Agreement. Research and development expenses were $13.4 million, up from $13.1 million in the prior year quarter, mainly due to increased investment in the PBGENE-DMD program, partially offset by decreases in the PBGENE-HBV and PBGENE-3243 programs. As of September 30, 2025, the company held approximately $71.2 million in cash, cash equivalents, and restricted cash. Precision BioSciences expects its current cash resources, along with anticipated near-term cash from CAR T transactions and operational efficiencies, to fund the company into the second half of 2027. During the quarter, the company commenced dosing in Cohort 3 of the ELIMINATE-B trial for PBGENE-HBV, advanced an IND filing for PBGENE-DMD expected by the end of 2025, and implemented expense reductions to extend its cash runway.